Pentetate Zinc Trisodium Zn DTPA

Sharing is caring!

What is Pentetate Zinc Trisodium Zn DTPA

Pentetate zinc trisodium Zn DTPA is a radiomitigation chelating agent indicated for the treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium.

Treatment with Zn-DTPA increases the rate of elimination of these radioactive contaminants.

When the sources of radiation contamination are multiple or unknown, other therapies (such as potassium iodide, insoluble Prussian blue, or sodium alginate) can be used in combination with Zn-DTPA. Chelation treatment should begin immediately, with contamination verified as soon as possible.

If treatment cannot be started right away, patients should begin therapy soon as it becomes available, as treatment is still effective even after time has elapsed since exposure.

Zn-DTPA should not be administered simultaneously with Ca-DTPA due to the duplicative nature of the treatments. If both products are available, Ca-DTPA should be given as the first dose.

If additional treatment is needed, treatment should be switched to Zn-DTPA, if Zn-DTPA is available.

This treatment sequence is recommended because Ca-DTPA is more effective than Zn-DTPA during the first 24 hours after internal contamination.

After the initial 24 hours, Zn-DTPA and Ca-DTPA are similarly effective, but Ca-DTPA causes more mineral loss.

The Zn-DTPA product labeling contains Black Box Warnings (BBW) regarding the potential for depletion of trace minerals and the potential for asthma exacerbation with inhaled administration

Indications

  • radiation exposure

For treatment of individuals with known or suspected internal contamination with radiation exposure to plutonium, americium, or curium to increase the rates of elimination

Side Effects

  1. cough
  2. dizziness
  3. headache
  4. pelvic pain
  5. wheezing

Monitoring Parameters

  • CBC with differential
  • serum creatinine/BUN
  • serum electrolytes
  • urinalysis

Contraindications

  • asthma
  • bone marrow suppression
  • breast-feeding
  • burns
  • children
  • dialysis
  • electrolyte imbalance
  • hypomagnesemia
  • infants
  • neonates
  • neutropenia
  • pregnancy
  • pulmonary disease
  • radiation exposure
  • renal failure
  • renal impairment
  • thrombocytopenia
  • trauma

Interactions

There are no drug interactions associated with Pentetate Zinc Trisodium, Zn-DTPA products.

Sharing is caring!

Status epilepticus

Status epilepticus What is status epilepticus?  Status epilepticus refers to...

You cannot copy content of this page

shares
15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top